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Novelty and Impact: This study synthesized direct evidence on the comparative 
effects of gefitinib, erlotinib and afatinib in non-small cell lung cancer. The three 
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agents had comparable efficacy in first-line treatment of patients with EGFR 
mutations, but gefitinib had a generally more favorable safety profile. Afatinib was 
more effective than erlotinib as second-line treatment of patients with advanced 
squamous cell carcinoma. These findings should inform clinical decision-making in 






Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor 
receptor tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non-small cell 
lung cancer (NSCLC) with proven efficacy. We undertook a systematic review and 
meta-analysis to synthesize existing studies with direct comparisons of EGFR TKIs in 
NSCLC in terms of both efficacy and safety. Eight randomized trials and 82 cohort 
studies with a total of 17621 patients were included for analysis. Gefitinib and 
erlotinib demonstrated comparable effects on progression-free survival (hazard ratio 
[HR], 1.00; 95% confidence interval [CI], 0.95 to 1.04), overall survival (HR, 0.99; 
95% CI, 0.93 to 1.06), overall response rate (risk ratio [RR], 1.05; 95% CI, 1.00 to 
1.11), and disease control rate (RR, 0.98; 95% CI, 0.96 to 1.01), which did not vary 
considerably with EGFR mutation status, ethnicity, line of treatment, and baseline 
brain metastasis status. Gefitinib was associated with more grade 3/4 liver dysfunction, 
but tended to have lower rates of dose reduction, treatment discontinuation, total 
grade 3/4 adverse events (RR, 0.78; 95% CI 0.65 to 0.94), and a number of specific 
adverse events such as rash and diarrhea. No solid evidence was found that afatinib 
had greater efficacy than gefitinib or erlotinib in first-line treatment of EGFR-mutant 
NSCLC. However, afatinib was more effective than erlotinib as second-line treatment 
of patients with advanced squamous cell carcinoma. The grade 3/4 adverse events rate 






Gefitinib and erlotinib are two small-molecule, first-generation epidermal growth 
factor receptor tyrosine kinase inhibitors (EGFR TKIs) that were approved more than 
10 years ago and have since been widely used as first-line treatment of advanced 
non-small cell lung cancer (NSCLC) in chemotherapy-naive patients, or as second- or 
later-line treatment after failure of chemotherapy.1 Compared with standard 
chemotherapy, EGFR TKIs are effective in improving progression-free survival but 
not overall survival.2 Greater efficacy of EGFR TKIs is associated with East Asian 
ethnicity, female sex, non-smoking status, adenocarcinoma pathological type,3,4 and 
most pronouncedly EGFR mutations.2 In particular, EGFR TKIs are superior to 
standard chemotherapy at various lines in EGFR-mutant NSCLC, but become inferior 
in EGFR-wild-type patients in terms of progression-free survival and overall response 
rate.2,5 In 2013, afatinib, a second-generation EGFR TKI, was also approved for 
treating advanced NSCLC. It is used as first-line treatment of patients with exon 19 
deletions or exon 21 (L858R) substitution mutations or second-line treatment of those 
with advanced squamous cell carcinoma after failure of platinum-based 
chemotherapy.6,7 
While the efficacy of gefitinib, erlotinib and afatinib is well established, their 
comparative effects are less understood, mainly because published randomized 
controlled trials that directly compared the three agents or any two of them are 
relatively rare.8-10 Indeed, there are good reasons to question the interchangeability of 
the three agents. For example, erlotinib and gefitinib are reversible EGFR TKIs, while 
afatinib is an irreversible ErbB-family blocker and reported to be effective against 
tumors carrying T790M mutation, a major mechanism for acquired resistance to 
EGFR TKIs.11 Gefitinib and erlotinib, who have similar chemical structures and 
mechanisms of action, are also different from each other in some aspects, which may 
lead to differential treatment effects. First, they differ in the substituents attached to 
the quinazoline and anilino rings, which may have important clinical implications.12 
Second, the pharmacokinetics of the two agents is also different. For example, when 
administered at their recommended doses (250 mg/day for gefitinib; 150 mg/day for 
erlotinib), the area under curve of the plasma concentrations of erlotinib is seven 
times higher than that of gefitinib.8,13 These differences have led to the assumption 
that erlotinib is more effective and at the same time associated with more adverse 
events than gefitinib. Indeed, studies have shown that gefitinib is effective in 
EGFR-mutant patients only, while erlotinib has efficacy versus placebo in 
EGFR-wild-type patients as well.3,14 
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Some researchers have tried to compare the three agents or two of them 
indirectly based on randomized controlled trials that evaluated each agent against 
control, in which no within-study direct comparisons of the agents were 
available.9,15-17 However, the indirect approach itself is controversial,18 and the 
findings from indirect comparisons conducted by different research groups were 
inconsistent. For example, Lee et al concluded that erlotinib was significantly more 
efficacious than gefitinib through indirect comparison based on two published trials, 
one for erlotinib (OPTIMAL) and one for gefitinib (IPASS),15 whereas Haaland et al 
stated that there was no statistically significant difference in the efficacy of the two 
agents based on eight trials involving gefitinib, erlotinib, and afatinib.17 
A review published in the New England Journal of Medicine in 2011 clearly 
pointed out that no direct comparison of gefitinib versus erlotinib had been conducted 
and thus no definitive conclusions could be drawn regarding their comparative 
effects.1 For the comparison of afatinib with gefitinib and erlotinib, a more recent 
review highlighted the same problem.10 In 2012, a phase II randomized controlled 
trial conducted in Korea directly compared gefitinib with erlotinib for the second-line 
treatment of advanced NSCLC, but it was small in sample size (48 patients for each 
group) and failed to yield any statistically significant results on progression-free 
survival, overall survival, overall response rate, disease control rate, or safety.8,19 To 
our knowledge, that was the only randomized trial with direct comparison of gefitinib 
with erlotinib that had been published in full text before the present systematic review 
started, although several relevant randomized trials emerged later. 
On the other hand, our pilot literature search showed that quite a number of 
observational cohort studies have been published to directly compare different EGFR 
TKIs in terms of effectiveness, safety, or both. However, a problem of such studies is 
that their results, compared with those of randomized controlled trials, are generally 
more susceptible to confounding. For example, due to lack of randomization, patient 
characteristics that may influence the efficacy of the two agents, such as female, 
non-smokers, adenocarcinoma, and EGFR mutation status, could be imbalanced 
between treatment groups. Here we report a systematic review and meta-analysis 
synthesizing the direct evidence, randomized or not, on the comparative effects of 




Data sources and literature search 
We performed a systematic search of PubMed, EMBASE, The Cochrane Central 
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Register of Controlled Trials, Chinese Biomedical Literature Database (in Chinese), 
and China National Knowledge Infrastructure (in Chinese) from their respective 
inception through 17 December 2016, limited to “human studies” where possible, 
with no restrictions placed on the time, language and format (abstract or full text) of 
publication. The keywords used for literature search included gefitinib, erlotinib, 
afatinib, non-small cell lung cancer, and their variations or synonyms. The abstracts of 
40 American Society of Clinical Oncology and European Society of Medical 
Oncology meetings, including their annual meetings and the meetings related to lung 
cancer, were reviewed, two major trial registration websites (i.e. 
www.clinicaltrials.gov/ and www.who.int/ictrp/) were searched, and the reference lists 
of eligible studies and relevant reviews were also scrutinized, to identify additional 
studies. 
Study selection 
Titles and abstracts of all identified records were screened to judge their relevance. 
Full texts of the studies seemingly fulfilling the inclusion criteria were obtained for 
further assessment. To be eligible for the present systematic review, original studies 
had to be randomized controlled trials or cohort studies that directly compared the 
three EGFR TKIs, i.e. gefitinib monotherapy, erlotinib monotherapy, afatinib 
monotherapy, or any two of them, in NSCLC patients and reported results on at least 
one of the following outcomes, i.e. progression-free survival, overall survival, overall 
response rate (complete response plus partial response), disease control rate (complete 
response plus partial response and stable disease), and safety, including treatment 
tolerability and adverse events. Completely duplicate records of a same study from 
different data sources were excluded, while partially duplicate records were combined 
to obtain a full picture of the study concerned. 
Data extraction 
The following data was extracted from each eligible study: (i) bibliographic 
information, such as first author, country, and publication year; (ii) clinical and 
pathological characteristics of patients, such as the number of patients included for the 
present systematic review, mean or median age, percentage of female, percentage of 
non-smokers, stage of cancer, pathological type of cancer, percentage of 
EGFR-mutant patients, Eastern Cooperative Oncology Group performance status, and 
line of treatment; (iii) main study results, such as hazard ratio (HR) and 95% 
confidence interval (CI) for progression-free survival, HR and 95% CI for overall 
survival, number of patients with response to treatment, and number of cases with 
adverse events; and (iv) information that did not belong to any of the previous 
7 
 
categories but was related to the methodological quality of studies (see the “risk of 
bias assessment” section below). 
Investigators of original studies were contacted as needed to clarify ambiguities 
in reported methods or results or to seek additional data not included in published 
reports. If not explicitly reported in original papers and still not available after contact 
with investigators, HRs were estimated based on other data reported, for example, 
survival curves, using such methods as the one developed by Parmar et al.20 Data 
extraction was completed independently by two reviewers. Disagreements between 
the two were settled by revisiting original papers and discussion until consensus was 
reached. 
Risk of bias assessment 
As mentioned above, both randomized controlled trials and cohort studies were 
included in this systematic review. The risk of bias in randomized controlled trials 
was assessed using the Cochrane Collaboration’s tool and classified as “low” or 
“others” for convenience of analysis.21 The Newcastle-Ottawa scale22 adapted to this 
systematic review was employed to assess the risk of bias in cohort studies, with 
emphasis on comparability between gefitinib and erlotinib groups in terms of the 
factors that are commonly believed to be able to significantly affect the efficacy of the 
two agents, such as ethnicity, gender, smoking status, pathology, EGFR mutation 
status, and line of treatment. According to the Newcastle-Ottawa scale, a score 
ranging from 0 to 9 was assigned to each study, with 9 representing the lowest risk of 
bias.22 For convenience of analysis, studies with a score of 7 to 9 were referred to as 
the low-risk-of-bias group. Risk of bias assessment was done independently by two 
reviewers. Disagreements between the two were resolved by revisiting the original 
paper and discussion. Unsettled disagreements were referred to a third researcher for 
final decision. 
Data synthesis and analysis 
The primary outcome was progression-free survival and secondary outcomes included 
overall survival, overall response rate, disease control rate, and safety. The 
comparative effects of EGFR TKIs on progression-free survival and overall survival 
were measured by HR with 95% CI, with HR>1 meaning that the efficacy of 
intervention group is inferior to that of reference group and HR<1 meaning the 
opposite. The comparative effects of overall response rate, disease control rate, and 
safety were measured by risk ratio (RR) with 95% CI. For overall response rate and 
disease control rate, RR>1 means that the efficacy of intervention group is greater 
than that of reference group, while RR<1 means the opposite. For safety, RR>1 means 
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that the safety profile of intervention group is worse than that of reference group, 
while RR<1 means the opposite.  
For each outcome, the effect estimates (HR or RR) from relevant studies were 
combined using the random-effects model to produce a summary estimate. Statistical 
heterogeneity among studies was measured by Cochran’s Q test and the I2 
statistic.23,24 A P value ≤0.10 for the Q test or an I2≥50% was suggestive of 
substantial heterogeneity. Subgroup analyses were conducted according to EGFR 
mutation status, ethnicity, line of treatment, and baseline brain metastasis status to see 
if the comparative effects of gefitinib versus erlotinib would vary with these important 
clinical factors and to explore the source of substantial heterogeneity, if present. 
Sensitivity analyses were conducted by restricting the meta-analyses to the studies 
with low risk of bias only to demonstrate the impact of study quality on the overall 
results. Begg’s funnel plot and Egger’s test were used to examine the possibility of 
publication bias where 10 or more studies were available.25 All analyses were 
performed with RevMan software, version 5.3 (Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2014), and STATA software, version 11.0 
(StataCorp LP, College Station, TX, USA). A P value <0.05 suggested statistical 
significance for all analyses except for the tests of heterogeneity and 




Study selection and characteristics 
The flow of study selection is shown in Figure 1. Of the 3208 records identified by 
our literature search, 90 eligible studies with 17621 patients (9529, 7401, and 691 in 
the gefitinib, erlotinib, and afatinib groups, respectively) were included for this 
systematic review.12,19,26-115 Twelve of the 90 studies were available as conference 
abstracts only.26-31,32-35,95,110,111 For one of the abstract-only studies, detailed results 
were obtained by communication with their investigators.34 The data of two studies 
were obtained from more than one source.36-39 
The characteristics of included studies are shown in Table 1. Except one global 
multicenter trial, most of the other studies were conducted in East Asia. Specifically, 
44 studies were from China, 13 from Korea, 12 from Japan, six from Taiwan, four 
from Italy, three from US, two from UK, two from Spain, and one each from 
Netherlands, France, and Thailand. Eighty studies were retrospective cohort studies, 
two prospective cohort studies,40,98 and eight randomized controlled 
trials.19,32,87,93,97,103,109,110 Eighty-eight studies (16014 patients), three studies (807 
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patients)89,97,98 and three studies (1047 patients) were available for the comparisons of 
gefitinib versus erlotinib, gefitinib versus afatinib, and erlotinib versus afatinib,89,98,103 
respectively, with two studies (607 patients) of them providing within-study 
comparison of the three agents.89,98 Twenty-nine studies included EGFR-mutant 
patients only, one study included EGFR-wide-type patients only, while the others 
included both or did not specify the EGFR status of patients. Fourteen studies were 
conducted in first-line settings, 21 in ≥second-line settings, and the others in both or 
did not specify the line of treatment. Fifty-one, 45, 61, 51, and 47 studies provided 
data on progression-free survival, overall survival, overall response rate, disease 
control rate, and safety, respectively. Twenty-five of the 90 eligible studies were 
regarded as with low risk of bias. 
Gefitinib versus erlotinib: efficacy 
Meta-analyses of studies with relevant data showed that the effects of gefitinib versus 
erlotinib on progression-free survival (HR, 1.00; 95% CI, 0.95 to 1.04, P=0.89; 
heterogeneity I2=56%, P<0.0001; Figure 2), overall survival (HR, 0.99; 95% CI, 0.93 
to 1.06, P=0.82; heterogeneity I2=42%, P=0.002; Figure 3), overall response rate (RR, 
1.05; 95% CI, 1.00 to 1.11, P=0.05; heterogeneity I2=0%, P=0.55; Appendix A), and 
disease control rate (RR, 0.98; 95% CI, 0.96 to 1.01, P=0.22; heterogeneity I2=0%, 
P=0.54; Appendix B) were all comparable. Substantial heterogeneity was observed in 
the meta-analyses for progression-free survival and overall survival. 
Gefitinib versus erlotinib: safety 
The results about safety are presented in detail in Appendix C. Briefly, there was a 
consistent trend towards fewer dose reduction (RR, 0.34; 95% CI, 0.21 to 0.54, 
P<0.0001; heterogeneity I2=32%, P=0.15), treatment discontinuation (RR 0.94; 95% 
CI 0.67 to 1.31, P=0.70; heterogeneity I2=25%, P=0.23), any-grade adverse events 
(RR, 0.92; 95% CI 0.75 to 1.14, P=0.47; heterogeneity I2=86%, P=0.0001), grade 3/4 
adverse events (RR, 0.78; 95% CI 0.65 to 0.94, P=0.01; heterogeneity I2=0%, P=0.72) 
and deaths due to adverse events (RR, 0.51; 95% CI 0.13 to 1.97, P=0.33; 
heterogeneity I2=0%, P=0.66) with gefitinib than with erlotinib, although only the 
results about dose reduction and grade 3/4 adverse events reached statistical 
significance. 
In terms of specific adverse events, gefitinib was associated with more grade 3/4 
liver dysfunction (RR, 2.88; 95% CI, 1.56 to 5.28, P=0.0007; heterogeneity I2=0%, 
P=0.68), but fewer grade 3/4 rash (RR, 0.43; 95% CI, 0.27 to 0.70, P=0.0005; 
heterogeneity I2=28%, P=0.11), any-grade diarrhea (RR, 0.83; 95% CI, 0.75 to 0.93, 
P=0.0007; heterogeneity I2=15%, P=0.23), any-grade nausea/vomiting (RR, 0.60; 
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95% CI, 0.43 to 0.85, P=0.003; heterogeneity I2=48%, P=0.02), and grade 3/4 
paronychia (RR, 0.19; 95% CI, 0.04 to 0.84, P=0.03; heterogeneity I2=0%, P=0.41) as 
compared with erlotinib. Gefitinib also appeared to be associated with lower 
incidence of some other adverse events such as asthenic conditions (RR 0.50; 95% CI, 
0.24 to 1.01, P=0.05), oral ulcer (RR 0.50; 95% CI, 0.25 to 1.04, P=0.06), pruritus 
(RR 0.72; 95% CI, 0.50 to 1.03, P=0.07), desquamation, eye change, stomatitis and 
constipation, but the results were not statistically significant, or the number of studies 
with relevant data was very limited. No significant difference was found in the 
incidence of such commonly mentioned adverse events as interstitial lung disease, 
neutropenia, anorexia and oral ulcer between the two treatment groups. 
Comparison of afatinib with gefitinib and erlotinib 
The effects of afatinib were investigated in four studies, including two 
observational ones directly comparing the three agents on progression-free survival89 
or selected adverse events,98 one randomized trial comparing afatinib with gefitinib on 
all efficacy and safety outcomes,97 and one randomized trial comparing afatinib with 
erlotinib on all efficacy and safety outcomes.103 
Compared with gefitinib, afatinib appeared to be associated with longer 
progression-free survival as first-line treatment of EGFR mutant patients,89,97 but the 
benefit was considerably different between studies (>18 versus 11.4 months in the 
observational one; 11.0 versus 10.9 months in the randomized trial), and there was no 
evidence that afatinib prolonged overall survival.97 
Compared with erlotinib, afatinib appeared to have similar efficacy in terms of 
progression-free survival as first-line treatment of EGFR mutant patients,89 but was 
associated with longer progression-free survival (2.6 vs 1.9 months, HR 0.81, 95% CI, 
0.69 to 0.96) and overall survival (7.9 vs 6.8 months, HR 0.81, 95% CI, 0.69 to 0.95) 
as second-line treatment of patients with advanced squamous cell carcinoma of the 
lung.103 
In terms of safety, there was a consistent trend that the overall incidence of grade 
3/4 adverse events of afatinib was comparable to that of erlotinib but higher than that 
of gefitinib.97,98,103 This finding coincides with the results on comparative effects of 
gefitinib versus erlotinib as reported above. Compared with gefitinib, afatinib caused 
more diarrhea and rash but fewer liver dysfunction.97 Compared with erlotinib, 
afatinib caused more diarrhea and stomatitis but fewer rash.103 
Subgroup, sensitivity and publication bias analyses 
Subgroup analyses showed that the comparative effects of gefitinib versus erlotinib 
did not differ considerably with EGFR mutation status, ethnicity, and line of treatment 
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(Appendix D). Although gefitinib appeared to be associated with better overall 
survival and fewer grade 3/4 adverse events in the first-line treatment subgroup, all 
subgroup differences were not statistically significant. Comparative effects of the two 
agents in the subset of patients with brain metastases were similar to those in the 
overall population. 
In sensitivity analyses where only the studies with low risk of bias were included, 
the summary estimates for progression-free survival, overall survival, overall 
response rate, disease control rate, any-grade adverse events, and grade 3/4 adverse 
events were 1.02 (95% CI 0.96~1.09, P=0.54; heterogeneity I2=37%, P=0.06), 1.00 
(95% CI 0.92~1.09, P=1.00; heterogeneity I2=0%, P=0.82), 1.01 (95% CI 0.91~1.11, 
P=0.91; heterogeneity I2=15%, P=0.29), 0.99 (95% CI 0.96~1.03, P=0.74; 
heterogeneity I2=0%, P=0.60), 0.92 (95% CI 0.75~1.14, P=0.47; heterogeneity 
I2=86%, P=0.0001),and 0.80 (95% CI 0.65~0.98, P=0.03; heterogeneity I2=0%, 
P=0.48), respectively, all of which were very close, both qualitatively and 
quantitatively, to the results of overall meta-analyses as reported above. However, the 
results of studies with low risk of bias tended to be more homogeneous than those in 
the overall meta-analyses.  
For the comparison of gefitinib with erlotinib, funnel plots constructed based on 
the data for progression-free survival, overall survival, overall response rate, disease 
control rate, and grade 3/4 adverse events are shown in Appendix E, which are all 
visually symmetric. Egger’s tests for asymmetry yielded no statistically significant 
results, indicating no evidence for publication bias. For the comparison of afatinib 




This systematic review synthesized 90 studies with direct comparisons of two or three 
EGFR TKIs, the majority of which comparing gefitinib with erlotinib. It was found 
that gefitinib had similar efficacy but a generally more favorable safety profile as 
compared with erlotinib. Specifically, gefitinib was associated with more grade 3/4 
liver dysfunction, but tended to have lower rates of dose reduction, treatment 
discontinuation, total adverse events, fatal or non-fatal, and a number of specific 
adverse events. The data on comparative effects of afatinib versus gefitinib or 
erlotinib is limited. There is no solid evidence that afatinib had greater efficacy, 
especially in terms of overall survival benefit, than the other two agents in first-line 
treatment of EGFR-mutant NSCLC. However, afatinib was more effective than 
erlotinib as second-line treatment of patients with advanced squamous cell carcinoma. 
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The overall grade 3/4 adverse events rate of afatinib was comparable to that of 
erlotinib but higher than that of gefitinib. 
These findings differ to varying degrees from those of previously published 
indirect comparisons of gefitinib with erlotinib.9,15-17 For example, Lee et al compared 
the gefitinib with erlotinib for first-line treatment of EGFR-mutant NSCLC indirectly 
based on only two large trials and concluded that erlotinib was significantly more 
efficacious than gefitinib (progression-free survival: HR=0.33, 95% CI 0.19 to 
0.58).15 Another three indirect comparisons of gefitinib, erlotinib and afatinib based 
on systematic review of randomized trials found that the three agents had similar 
efficacy.9,16,17 Among these indirect comparisons, however, Haaland et al (11 trials, 3 
EGFR TKIs and various chemotherapies) found that the “adverse event profiles were 
similar among TKIs”;16 Liang et al (12 trials, 4 EGFR TKIs and various 
chemotherapies) found that gefitinib was associated with fewer grade 3/4 rash and 
diarrhea than erlotinib and afatinib;17 Haspinger et al (9 trials, 3 EGFR TKIs and 
various chemotherapies) found that gefitinib was associated with similar rates of 
diarrhea and rash, but more hypertransaminasemia, as compared with erlotinib, and 
that both agents caused lower adverse events rates than did afatinib.9 The discrepancy 
between these indirect comparisons is obvious. It could be due to the different number 
of studies, patients and treatments included for comparison, or even the validity of the 
indirect approach itself. The present systematic review settled existing controversies 
by including studies with direct comparison of EGFR TKIs only. It provides a full 
view of the comparative effects of gefitinib, erlotinib and afatinib on a variety of 
outcomes. 
The finding that gefitinib and erlotinib have comparable efficacy but different 
safety profiles is not completely the same as expected. Although the bioavailability of 
erlotinib 150 mg/day (equal to the maximum tolerated dose) is three-fold higher than 
that of gefitinib 250 mg/day (one-third of the maximum tolerated dose),116,117 which 
could partly explain the less tolerability and more toxicities with erlotinib, the 
anticancer efficacy of erlotinib is however not greater than that of gefitinib. A 
potential explanation for this is that gefitinib, after absorbed, accumulates 
significantly more in tumor tissue than in plasma, in contrast with the clinical 
pharmacokinetics of erlotinib.118,119 
The findings of this systematic review have important clinical implications. As 
there is no solid evidence that gefitinib, erlotinib and afatinib differ much in efficacy, 
gefitinib seems to be generally more preferable than the other two agents, in view of 
their safety profiles, for first-line treatment of patients with EGFR-mutant NSCLC. 
For second-line treatment of advanced squamous cell carcinoma, currently available 
evidence suggests that afatinib is generally a better choice than erlotinib. However, 
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this does not necessarily mean that gefitinib and afatinib are always optimal in the two 
settings, respectively. Clinical decision-making regarding which agent to use should 
also take patients’ physical status, resources and values into account, which is often 
not straightforward. For example, gefitinib could be more suitable for patients with 
poor gastrointestinal function, while erlotinib or afatinib could be better for those with 
poor liver functions. In addition, the prices of and reimbursement or discounting 
schemes for different agents, if any, could be different within health systems.48,57,72,120 
Thus, the out-of-pocket costs of different EGFR TKIs treatments should be balanced 
against the suffering from and costs required for management of toxicities induced by 
these agents.  
This systematic review has several strengths. First, it summarized the direct 
evidence on comparative effects of different EGFR TKIs, which is scientifically more 
solid than indirect evidence. Second, it compiled a large, comprehensive dataset, 
which allowed us to obtain precise estimates and conduct subgroup analyses 
according to important factors. Importantly, there was no evidence for publication 
bias. Third, between-study statistical heterogeneity was not significant in most of the 
main meta-analyses, especially in the ones restricted to studies with low risk of bias. 
Although the majority of included studies were observational and potential imbalance 
in patient characteristics between gefitinib and erlotinib groups could be of concern, 
sensitivity analyses that included the studies with low risk of bias only showed that 
the summary estimates were robust and very close to those from the overall 
meta-analyses.  
A major limitation of this systematic review is that the number of studies 
available for comparison of afatinib with gefitinib, erlotinib, or both, was very limited. 
This prevented us from drawing a firm conclusion about their comparative effects in 
some settings. For example, for second-line treatment of advanced squamous cell 
carcinoma, currently available evidence suggests that afatinib has greater efficacy 
than does erlotinib, but whether afatinib outperforms gefitinib or not in risk-benefit 
ratio is unclear. The same question exists in some other settings as well and thus 
remains to be clarified. A further limitation of the present work is that data on 
low-grade adverse events are lacking, mainly because most of the included studies did 
not report them separately. Low-grade adverse events may impair patient’ quality of 
life more than transient grade 3/4 adverse events. Thus, future studies are suggested to 
pay attention to this issue. 
As shown by this systematic review, dose reduction occurs significantly more in 
erlotinib group than in gefitinib group, but the two groups achieved comparable 
efficacy. This implies that erlotinib might be administered at a lower-than-standard 
dose to reduce adverse events while retaining its efficacy. In fact, retrospective studies 
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have shown that patients who were treated with reduced dose of erlotinib down to 25 
mg/day had similar or even better prognosis compared to those who were treated with 
the agent at standard dose, although prospective studies are needed to validate this 
finding.121-123 To complicate matters, similar evidence exists for gefitinib as 
well.121,124,125 Thus, there seems to be room for adjusting the doses of both agents to 
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Figure 1. Flow chart of study selection. 
 
Figure 2. Comparative effects of gefitinib versus erlotinib on progression-free 
survival of patients with non-small cell lung cancer. Results are presented as 
individual and pooled hazard ratios with 95% confidence intervals. A hazard ratio 
statistically significantly smaller than 1 means that the progression-free survival of 
patients treated with gefitinib is better than with erlotinib, while a hazard ratio 
statistically significantly greater than 1 means the opposite. 
 
Figure 3. Comparative effects of gefitinib versus erlotinib on overall survival of 
patients with non-small cell lung cancer. Results are presented as individual and 
pooled hazard ratios with 95% confidence intervals. A hazard ratio statistically 
significantly smaller than 1 means that the overall survival of patients treated with 
gefitinib is better than that with erlotinib, while a hazard ratio statistically 
significantly greater than 1 means the opposite. 
 
